Endocrinology, Vol 137, 219-224, Copyright © 1996 by Endocrine Society

ARTICLES

Tamoxifen-induced proto-oncogene expression persists in uterine endometrial epithelium

KP Nephew, TC Polek and SA Khan
Department of Cell Biology, Neurobiology, and Anatomy, College of Medicine, University of Cincinnati, Ohio 45267-0521, USA.

The use of the antiestrogen tamoxifen for breast cancer management, although generally well tolerated, is linked to an increase in uterine pathologies in a high number of postmenopausal women receiving the drug. This effect is thought to be due to estrogenic stimulation of the uterine endometrium by the antiestrogen; however, the molecular mechanism underlying the uterotrophic activity of tamoxifen and the uterine cellular compartments that respond to the drug have not been clearly established. In this study, we determined which of the several uterine tissues (myometrium, stroma, and luminal and glandular epithelium) demonstrated chronic overexpression of c-fos and the jun proto-oncogenes in response to tamoxifen. Uteri from tamoxifen-treated, castrated rats were examined histologically, and cell type-specific expression of c-fos, c-jun, jun-B, and jun-D was assessed using in situ hybridization. Treatment with tamoxifen resulted in uterine luminal and glandular epithelial hypertrophy and basally located nuclei by 36 h. Extreme uterine glandular and luminal epithelial cell hypertrophy persisted 7 days after administration of the drug. Expression of c-fos and jun-B messenger RNA was first detected in the luminal and glandular epithelial at 12-36 h post tamoxifen injection. Seven days after tamoxifen treatment, c-fos and jun-B messenger RNA levels were lower but still evident in the uterine endometrial epithelium. Tamoxifen completely repressed constitutive expression of c-jun in the uterine luminal epithelial cells by 12 h but, unlike estrogen, did not induce c- jun expression in the uterine myometrium. Expression of jun-D in the uterine glandular and luminal epithelia was observed at 12 h but not at 24 h post tamoxifen. These results support our working hypothesis that persistent overexpression of cellular oncogenes c-fos and jun-B in the uterine endometrial epithelium may contribute to the molecular mechanism underlying the uterine toxicity associated with chronic tamoxifen treatment.

This article has been cited by other articles:

				D. W. Singleton, Y. Feng, C. J. Burd, and S. A. Khan Nongenomic Activity and Subsequent c-fos Induction by Estrogen Receptor Ligands Are Not Sufficient to Promote Deoxyribonucleic Acid Synthesis in Human Endometrial Adenocarcinoma Cells Endocrinology, January 1, 2003; 144(1): 121 - 128. [Abstract] [Full Text] [PDF]

				M. Fan, X. Long, J. A. Bailey, C. A. Reed, E. Osborne, E. A. Gize, E. A. Kirk, R. M. Bigsby, and K. P. Nephew The Activating Enzyme of NEDD8 Inhibits Steroid Receptor Function Mol. Endocrinol., February 1, 2002; 16(2): 315 - 330. [Abstract] [Full Text] [PDF]

				H. Huynh, C. Y. Ng, K. B. Lim, C. K. Ong, C. S. Ong, E. Tran, T. T. Tuyen Nguyen, and T. W. M. G. Chan Induction of UO-44 Gene Expression by Tamoxifen in the Rat Uterus and Ovary Endocrinology, July 1, 2001; 142(7): 2985 - 2995. [Abstract] [Full Text] [PDF]

				R. Stackievicz, L. Drucker, J. Radnay, Y. Beyth, S. Yarkoni, and I. Cohen Tamoxifen Modulates Apoptotic Pathways in Primary Endometrial Cell Cultures Clin. Cancer Res., February 1, 2001; 7(2): 415 - 420. [Abstract] [Full Text]

				K. P. Nephew, S. Ray, M. Hlaing, A. Ahluwalia, S. D. Wu, X. Long, S. M. Hyder, and R. M. Bigsby Expression of Estrogen Receptor Coactivators in the Rat Uterus Biol Reprod, August 1, 2000; 63(2): 361 - 367. [Abstract] [Full Text]

				K. P. Nephew, E. Osborne, R. A. Lubet, C. J. Grubbs, and S. A. Khan Effects of Oral Administration of Tamoxifen, Toremifene, Dehydroepiandrosterone, and Vorozole on Uterine Histomorphology in the Rat Experimental Biology and Medicine, March 1, 2000; 223(3): 288 - 294. [Abstract] [Full Text]

				K. P. Nephew, X. Long, E. Osborne, K. A. Burke, A. Ahluwalia, and R. M. Bigsby Effect of Estradiol on Estrogen Receptor Expression in Rat Uterine Cell Types Biol Reprod, January 1, 2000; 62(1): 168 - 177. [Abstract] [Full Text]

				M. Berliere, C. Galant, and J. Donnez Case Report:The potential oncogenic effect of tamoxifen on the endometrium Hum. Reprod., May 1, 1999; 14(5): 1381 - 1383. [Abstract] [Full Text] [PDF]